Glaxosmithkline Pharmaceuticals quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	938	805	+16.6%
EBITDA	296	251	+17.6%
EBITDA margin	31.5%	31.2%	+0.3 pts
Profit before tax	322	279	+15.6%
Net profit	237	205	+15.7%
EPS	₹14.00	₹12.10	+15.7%

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Q2 FY24Sep 2023	Earlier quartersAlpha Plus

Expenses
	938	995	1,041	980	805	974	949	1,011	815	930	805	957	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	43.8	36.0	32.1	33.6	43.7	40.7	35.1	34.5	35.6	29.8	28.1	28.2
	982	1,031	1,073	1,014	849	1,015	984	1,045	850	960	833	985
	73.0	113	79.9	115	128	115	97.5	149	138	205	91.0	91.2
	379	228	217	233	232	291	164	217	173	256	163	261
	−124	2.5	66.7	7.7	−72.4	−54.7	97.5	18.8	−15.7	−93.2	63.4	2.6
	159	165	152	138	153	153	125	151	151	173	141	145
	1.0	0.6	1.2	0.5	0.4	0.6	0.1	0.3	0.4	0.8	0.3	0.4
	15.8	13.2	20.3	17.4	15.5	14.7	18.8	16.9	16.4	18.1	17.1	18.1
	156	136	154	151	114	136	174	154	138	133	129	168
	660	658	691	662	570	656	676	706	601	691	605	686
	296	351	371	336	251	333	292	322	231	257	218	289
	280	338	351	318	236	318	273	305	214	239	201	271
Profit
	322	373	382	351	279	359	308	339	249	268	229	299
	0.0	0.0	18.0	2.6	0.0	0.0	0.0	4.7	0.0	2.4	−163	0.0
	322	373	400	354	279	359	308	344	249	271	65.4	299
	82.0	88.3	102	96.1	74.0	90.2	73.5	98.8	63.6	61.7	31.4	91.3
	3.3	7.0	2.1	0.4	0.0	5.6	4.7	−7.5	3.5	14.5	−11.7	−9.6
	85.3	95.2	104	96.5	74.0	95.7	78.2	91.3	67.1	76.1	19.7	81.7
	237	278	296	257	205	263	230	253	182	194	45.7	218
	237	278	296	257	205	263	230	253	182	194	45.7	218
	0.0	−13.7	6.2	0.0	0.0	−3.8	1.2	0.0	0.0	−0.7	−3.5	0.0
	237	264	302	257	205	259	231	253	182	194	42.2	218
	—	—	—	257	205	263	—	—	182	194	45.7	218
Per share
	₹14.00	₹16.40	₹16.54	₹15.07	₹12.10	₹15.52	₹13.57	₹14.67	₹10.76	₹11.48	₹9.89	₹12.84
	₹14.00	₹16.40	₹17.45	₹15.20	₹12.10	₹15.52	₹13.57	₹14.91	₹10.76	₹11.48	₹2.70	₹12.84
Other comprehensive income — detail
	—	−13.7	6.2	0.0	—	−3.8	—	—	—	—	—	—
	—	−18.3	8.3	—	—	−5.1	1.6	—	—	−0.9	−4.7	—
	—	−4.5	2.1	0.0	—	−1.3	—	—	—	—	—	—
	—	—	—	—	—	—	0.4	0.0	—	−0.2	−1.2	—
	—	—	—	257	205	—	—	—	182	194	42.2	218
Per share — as-filed variants
	₹14.00	₹16.40	₹16.54	₹15.07	₹12.10	₹15.52	₹13.57	₹14.67	₹10.76	₹11.48	₹9.89	₹12.84
	₹14.00	₹16.40	₹17.45	₹15.20	₹12.10	₹15.52	₹13.57	₹14.91	₹10.76	₹11.48	₹2.70	₹12.84
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	611	651	677	624	517	622	590	626	519	563	488	603
	65.1%	65.4%	65.1%	63.7%	64.3%	63.9%	62.2%	62.0%	63.8%	60.5%	60.7%	63.0%
Adjusted (ex-exceptional items) — derived
	322	373	382	351	279	359	308	339	249	268	229	299
	0.0	0.0	18.0	2.6	0.0	0.0	0.0	4.7	0.0	2.4	−163	0.0
	237	278	282	256	205	263	230	249	182	193	160	218
	₹14.00	₹16.40	₹15.80	₹14.96	₹12.10	₹15.52	₹13.57	₹14.47	₹10.76	₹11.38	₹34.57	₹12.84

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

GLAXO₹2,498.00

Glaxosmithkline Pharmaceuticals Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersPFIZER ABBOTINDIA MEDANTA ANTHEM AJANTPHARM IPCALAB GLENMARK BIOCONMcap ₹42,319 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	957.0	805.3	929.8	814.7	1,010.8	949.4	974.4	805.2	979.9	1,041.3	995.3	938.4
Other Income	28.2	28.1	29.8	35.6	34.5	35.1	40.7	43.7	33.6	32.1	36.0	43.8
Total Income	985.2	833.4	959.6	850.3	1,045.3	984.5	1,015.1	848.9	1,013.5	1,073.4	1,031.3	982.2
Expenses
+ Cost of Materials Consumed	91.2	91.0	204.6	138.2	149.0	97.5	115.2	128.1	115.1	79.9	113.1	73.0
+ Purchases of Stock-in-Trade	260.6	162.5	255.7	172.7	216.7	164.2	291.4	232.1	232.7	217.3	228.4	378.6
+ Changes in Inventories	2.6	63.4	-93.2	-15.7	18.8	97.5	-54.7	-72.4	7.7	66.7	2.5	-123.6
+ Employee Benefit Expense	145.2	141.4	172.8	151.3	150.7	124.7	153.0	152.6	138.1	151.9	164.8	159.0
+ Finance Costs	0.4	0.3	0.8	0.4	0.3	0.1	0.6	0.4	0.5	1.2	0.6	1.0
+ Depreciation & Amortisation	18.1	17.1	18.1	16.4	16.9	18.8	14.7	15.5	17.4	20.3	13.2	15.8
+ Other Expenses	167.9	129.0	132.6	137.6	153.9	173.6	136.3	113.7	150.6	154.2	135.6	156.0
Total Expenses	686.0	604.6	691.4	600.9	706.2	676.4	656.5	569.9	662.2	691.4	658.2	659.8
EBITDA	289.5	218.1	257.3	230.5	321.7	291.9	333.2	251.2	335.7	371.3	350.9	295.5
EBIT	271.4	201.0	239.2	214.1	304.9	273.1	318.5	235.7	318.3	351.0	337.8	279.7
Profit
PBT before Exceptional Items	299.2	228.7	268.2	249.4	339.1	308.1	358.6	279.0	351.4	382.0	373.1	322.5
+ Exceptional Items	0.0	-163.3	2.4	0.0	4.7	0.0	0.0	0.0	2.6	18.0	0.0	0.0
Pretax Income	299.2	65.4	270.6	249.4	343.8	308.1	358.6	279.0	354.0	399.9	373.1	322.5
+ Current Tax	91.3	31.4	61.7	63.6	98.8	73.5	90.2	74.0	96.1	102.3	88.3	82.0
+ Deferred Tax	-9.6	-11.7	14.5	3.5	-7.5	4.7	5.6	0.0	0.4	2.1	7.0	3.3
Tax Expense	81.7	19.7	76.1	67.1	91.3	78.2	95.7	74.0	96.5	104.3	95.2	85.3
Net Income	217.5	45.7	194.5	182.3	252.5	229.9	262.9	205.0	257.5	295.6	277.9	237.2
+ Net Income — Continuing Ops	217.5	45.7	194.5	182.3	252.5	229.9	262.9	205.0	257.5	295.6	277.9	237.2
+ Other Comprehensive Income	0.0	-3.5	-0.7	0.0	0.0	1.2	-3.8	0.0	0.0	6.2	-13.7	0.0
Total Comprehensive Income	217.5	42.2	193.8	182.3	252.5	231.1	259.0	205.0	257.5	301.8	264.1	237.2
Net Income to Common	217.5	45.7	194.5	182.3	—	—	262.9	205.0	257.5	—	—	—
Per Share
Basic EPS	12.84	9.89	11.48	10.76	14.67	13.57	15.52	12.10	15.07	16.54	16.40	14.00
Diluted EPS	12.84	2.70	11.48	10.76	14.91	13.57	15.52	12.10	15.20	17.45	16.40	14.00
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	-3.8	—	0.0	6.2	-13.7	—
+ Items NOT to be Reclassified to P&L	—	-4.7	-0.9	—	—	1.6	-5.1	—	—	8.3	-18.3	—
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	-1.3	—	0.0	2.1	-4.5	—
+ Tax on Items NOT to be Reclassified — alt tag	—	-1.2	-0.2	—	0.0	0.4	—	—	—	—	—	—
Comprehensive Income — Owners of Parent	217.5	42.2	193.8	182.3	—	—	—	205.0	257.5	—	—	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	12.84	9.89	11.48	10.76	14.67	13.57	15.52	12.10	15.07	16.54	16.40	14.00
Diluted EPS — Continuing Operations	12.84	2.70	11.48	10.76	14.91	13.57	15.52	12.10	15.20	17.45	16.40	14.00
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	602.6	488.4	562.7	519.4	626.3	590.3	622.4	517.5	624.4	677.4	651.3	610.5
Gross Margin %	62.96	60.65	60.52	63.75	61.96	62.17	63.88	64.27	63.72	65.06	65.44	65.05
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	299.2	228.7	268.2	249.4	339.1	308.1	358.6	279.0	351.4	382.0	373.1	322.5
− Exceptional Items (reconciliation)	0.0	-163.3	2.4	0.0	4.7	0.0	0.0	0.0	2.6	18.0	0.0	0.0
Net Income Adj (tax-effected)	217.5	159.8	192.8	182.3	249.1	229.9	262.9	205.0	255.6	282.3	277.9	237.2
EPS Adj	12.84	34.57	11.38	10.76	14.47	13.57	15.52	12.10	14.96	15.80	16.40	14.00
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00
Paid Up Equity Capital	169.4	169.4	169.4	169.4	169.4	169.4	169.4	169.4	169.4	169.4	169.4	169.4

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Glaxosmithkline Pharmaceuticals Q2 FY27 results date

Glaxosmithkline Pharmaceuticals (NSE: GLAXO) will announce its Q2 FY27 results (July–September 2026) on Tuesday, 3 November 2026, according to the board-meeting notice it filed on 13 October 2026. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit was ₹237 crore, up 15.7% from ₹205 crore in Q1 FY26 and down 14.6% from ₹278 crore in Q4 FY26. Revenue from operations was ₹938 crore, up 16.6% year on year and down 5.7% from the previous quarter.

Board-meeting notice filed: 13 October 2026
Q1 FY27 results (the latest): 3 August 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results date: 3 November 2026Tuesday · notice filed 13 Oct
Q1 FY27 net profit: ₹237 Cr+15.7% vs Q1 FY26−14.6% vs Q4 FY26
Q1 FY27 revenue: ₹938 Cr+16.6% vs Q1 FY26−5.7% vs Q4 FY26
Q1 FY27 operating margin: 29.8%+0.5 pts vs Q1 FY26−4.1 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹257 CrRevenue ₹980 Cr
Q1 FY27 EPS (basic): ₹14.00

Questions

When will Glaxosmithkline Pharmaceuticals announce its Q2 FY27 results?

On 3 November 2026, the date of the board meeting called to approve them (notice filed with the exchanges on 13 October 2026).

What was Glaxosmithkline Pharmaceuticals' net profit in FY26?

Consolidated net profit was ₹1,036 crore in FY26 (April 2025–March 2026), up 11.7% from ₹928 crore in FY25. It was ₹590 crore in FY24 and ₹611 crore in FY23: up 69.6% over three years, 19.3% a year on average.

What was Glaxosmithkline Pharmaceuticals' revenue in FY26?

Revenue from operations was ₹3,822 crore in FY26 (April 2025–March 2026), up 1.9% from ₹3,749 crore in FY25. It was ₹3,454 crore in FY24 and ₹3,252 crore in FY23: up 17.5% over three years, 5.5% a year on average.

What will Glaxosmithkline Pharmaceuticals' Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit was ₹257 crore and revenue from operations ₹980 crore. The latest quarter, Q1 FY27, had a net profit of ₹237 crore and revenue of ₹938 crore.

What were Glaxosmithkline Pharmaceuticals' Q1 FY27 results?

Consolidated net profit was ₹237 crore, up 15.7% from ₹205 crore in Q1 FY26 and down 14.6% from ₹278 crore in Q4 FY26. Revenue from operations was ₹938 crore, up 16.6% year on year and down 5.7% from the previous quarter.

How has Glaxosmithkline Pharmaceuticals' profit changed over the last four quarters?

Net profit by quarter: ₹257 crore in Q2 FY26, ₹296 crore in Q3 FY26, ₹278 crore in Q4 FY26 and ₹237 crore in Q1 FY27. That is ₹1,068 crore over the four quarters, up 12.4% from ₹950 crore in the four quarters before. Revenue from operations: ₹980 crore, ₹1,041 crore, ₹995 crore and ₹938 crore.

Where do these Glaxosmithkline Pharmaceuticals figures come from?

From Glaxosmithkline Pharmaceuticals' own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.